Brief: Filana Therapeutics - FDA Lifts Clinical Hold On Filana's Simufilam For TSC-Related Epilepsy
22/09/2026 13:45
BRIEF-Filana Therapeutics - FDA Lifts Clinical Hold On Filana's Simufilam For TSC-Related Epilepsy Sept 22 (Reuters) - Filana Therapeutics, Inc. FLNA.O:
FILANA THERAPEUTICS ANNOUNCES FDA LIFT OF CLINICAL HOLD ON SIMUFILAM, ENABLING PHASE 2A STUDY IN TSC-RELATED EPILEPSY
FILANA THERAPEUTICS, - FDA LIFTS CLINICAL HOLD ON FILANA'S SIMUFILAM FOR TSC-RELATED EPILEPSY
FILANA THERAPEUTICS, - PATIENT SCREENING FOR PHASE 2A STUDY EXPECTED TO BEGIN BY Q1 2027
FILANA THERAPEUTICS, - PHASE 2A STUDY TO ENROLL 40 SUBJECTS AT 13 U.S. SITES OVER 16 WEEKS
FILANA THERAPEUTICS, - SUBJECTS ELIGIBLE FOR 48-WEEK EXTENSION STUDY AFTER DOUBLE-BLIND PHASE
Source text: ID:nGNX1L0hXX
Further company coverage: FLNA.O
((Reuters.Briefs@thomsonreuters.com))